Ceftriaxone + edta
Reading File
Finding Sources
Searching PubMed
ceftriaxone EDTA antimicrobial combination
Searching the Web
ceftriaxone EDTA combination mechanism uses clinical
Searching PubMed
ceftriaxone sulbactam EDTA ESBL MBL infections
Reading Web Page
https://globalresearchonline.net/ijpsrr/v82-1/10.pdf
Here is a structured overview of Ceftriaxone + EDTA (and the full CSE triple combination):
Ceftriaxone + EDTA (Disodium Edetate)
What it is
In clinical practice, EDTA (ethylenediaminetetraacetic acid) is almost always used as part of a three-drug fixed-dose combination (FDC) with ceftriaxone and sulbactam - commonly called CSE or marketed in India as Elores (Ceftriaxone 1g + Sulbactam 500mg + Disodium EDTA 37mg, IV).
Individual Roles in the Combination
| Component | Role |
|---|---|
| Ceftriaxone | 3rd-gen cephalosporin; bactericidal via beta-lactam ring inhibiting PBP and blocking cell wall synthesis |
| Sulbactam | Beta-lactamase inhibitor (BLI); protects ceftriaxone from hydrolysis by ESBLs (extended-spectrum beta-lactamases) |
| Disodium EDTA | Non-antibiotic adjuvant / "antibiotic resistance breaker" |
Mechanism of EDTA in this Combination
EDTA works through multiple synergistic mechanisms:
-
Metallo-beta-lactamase (MBL) inhibition - EDTA chelates the divalent zinc (Zn²+) ions in the active site of metallo-beta-lactamases (MBL: NDM-1, VIM, IMP types). Since MBLs require Zn²+ for catalytic activity, chelation effectively deactivates MBLs, restoring ceftriaxone activity.
-
Enhanced outer membrane permeability - Gram-negative bacterial outer membranes are stabilized by Ca²+ and Mg²+. EDTA chelates these divalent cations, destabilizing the outer membrane (LPS layer), which increases intracellular penetration of ceftriaxone and sulbactam.
-
Efflux pump inhibition - Efflux pumps (a major resistance mechanism) require Ca²+ as an energy source. By chelating Ca²+, EDTA disables efflux pumps, preventing the bacterium from expelling ceftriaxone.
-
Anti-biofilm activity - EDTA disrupts the structural integrity of biofilms (which are also stabilized by divalent cations). This helps access and kill organisms embedded in biofilm on devices/catheters.
Spectrum of Activity (CSE combination)
Primarily targets MDR Gram-negative pathogens, including WHO Critical Priority organisms:
- Klebsiella pneumoniae (ESBL/MBL-producing)
- Escherichia coli (ESBL-producing)
- Acinetobacter baumannii (MDR/XDR)
- Pseudomonas aeruginosa (MDR)
- Enterobacteriaceae (carbapenem-resistant, MBL-producing)
Clinical Indications
- Complicated urinary tract infections (cUTI) and acute pyelonephritis due to ESBL producers
- Hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP)
- Bloodstream infections (BSIs) - nosocomial/MDR
- Lower respiratory tract infections (LRTIs)
- Biofilm-associated infections (e.g., catheter-related)
- Infections caused by ESBL + MBL co-producing organisms
Key Clinical Evidence
- PLEA Trial (IDWeek 2018): Randomized 143 patients with cUTI/pyelonephritis. CSE (every 12 hours) was superior to meropenem in ESBL infections and non-inferior in MDR/ceftriaxone-nonsusceptible pathogens.
- ESBL clinical cure rate: CSE ~80.3% vs ceftriaxone alone ~30.8%; bacterial eradication ~85.3% vs 23.1%.
- vs. Meropenem + colistin: CSE + colistin showed significantly better bacteriological and clinical efficacy in nosocomial MDR Gram-negative infections (JCDR 2016).
- In vitro vs WHO Critical Priority Pathogens: High susceptibility in ESBL- and MBL-producing A. baumannii, P. aeruginosa, and Enterobacteriaceae (Singh et al., IJCCM 2020, PMID: 33446975).
Role as a "Carbapenem Sparer"
The central clinical rationale for CSE is carbapenem-sparing therapy. Carbapenems are "last-resort" antibiotics; overuse drives carbapenem resistance. CSE offers an alternative for ESBL and MBL producers that would otherwise require carbapenems, helping preserve carbapenem activity.
Approved by the Drug Controller General of India (DCGI) after Phase III trials. Primarily used in India and select Asian markets.
Key Abbreviations
- CSE = Ceftriaxone + Sulbactam + EDTA
- ESBL = Extended-Spectrum Beta-Lactamase
- MBL = Metallo-Beta-Lactamase (Zn-dependent; e.g., NDM-1, VIM, IMP)
- ARB = Antibiotic Resistance Breaker (term for EDTA's role)
- Elores = Brand name of CSE in India
How it has to be given? Means in 100ml or infusion,time vs peak concentration?
Finding Sources
Searching the Web
Elores CSE ceftriaxone sulbactam EDTA infusion administration time reconstitution dosing IV
Searching PubMed
ceftriaxone pharmacokinetics peak concentration infusion time
Reading Web Page
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/06…
Searching the Web
Elores ceftriaxone sulbactam EDTA 100ml NS infusion reconstitution administration instructions
Here is a complete breakdown of administration and pharmacokinetics:
CSE (Ceftriaxone + Sulbactam + EDTA) - Administration & PK
Step-by-Step IV Administration
Step 1 - Reconstitution:
- Add 10 mL of Water for Injection (WFI) to the vial
- Each 1 mL of reconstituted solution = ~100 mg of ceftriaxone
Step 2 - Dilution:
- Withdraw the reconstituted solution and add to 100 mL of Normal Saline (0.9% NaCl) or 5% Dextrose
- This gives a final concentration of ~10 mg/mL (for a 1g dose in 100 mL) - well within the recommended 10-40 mg/mL range
Step 3 - Infusion:
- Infuse the 100 mL bag over 30 minutes (constant-rate infusion)
- In neonates: infuse over 60 minutes (to reduce risk of bilirubin encephalopathy due to displacement from albumin)
Standard adult dose of Elores: Ceftriaxone 1g + Sulbactam 500mg + EDTA 37mg IV every 12 hours
Critical Compatibility Warning
| Avoid | Reason |
|---|---|
| Ringer's Lactate / Hartmann's solution | Contains calcium - precipitates with ceftriaxone |
| Calcium gluconate in the same line | Same precipitation risk |
| TPN (Total Parenteral Nutrition) | Contains calcium - must not run simultaneously |
| Simultaneous Y-site with calcium | Dangerous precipitate, especially in neonates |
Preferred diluents: 0.9% Normal Saline or 5% Dextrose only.
Time vs. Peak Concentration (FDA Data - Single Dose IV)
Ceftriaxone plasma concentrations after constant-rate 30-minute IV infusion:
| Dose | Peak (end of infusion) | 1 hr | 2 hr | 4 hr | 8 hr | 12 hr | 16 hr | 24 hr |
|---|---|---|---|---|---|---|---|---|
| 0.5 g IV | ~82 mcg/mL | ~59 | ~48 | ~37 | ~29 | ~23 | ~15 | ~7 |
| 1 g IV | ~151 mcg/mL | ~111 | ~88 | ~67 | ~53 | ~43 | ~28 | ~11 |
| 2 g IV | ~257 mcg/mL | ~192 | ~154 | ~117 | ~89 | ~74 | ~46 | ~17 |
- Peak (Cmax) is reached at the END of the 30-minute infusion (not after)
- After the infusion ends, levels decline in a biphasic manner
Why 30 Minutes Matters - PK/PD Concept
Ceftriaxone is a time-dependent antibiotic. Its killing efficacy depends on:
T > MIC = time the free drug concentration stays above the MIC of the pathogen
So infusing faster (e.g., 5-10 min bolus) would give a higher but brief peak that drops quickly - not beneficial. Infusing over 30 minutes maintains adequate concentrations across the infusion window and into the post-infusion period.
| Parameter | Value |
|---|---|
| Protein binding | 83-96% (highly protein-bound) |
| Half-life (t½) | 6-9 hours (unusually long for a cephalosporin) |
| Volume of distribution | ~6-14 L |
| Elimination | Dual - biliary (~40-50%) + renal (~40-65%) |
The long half-life of ceftriaxone (6-9 hrs) is what allows once-daily or twice-daily dosing - concentrations remain above MIC for most pathogens throughout the dosing interval.
Elores-Specific Note (CSE triple combination)
The EDTA and sulbactam components do not significantly alter ceftriaxone's PK profile. The 30-minute infusion rule still applies. The combination is given every 12 hours (not once daily) in MDR infections to maintain trough levels adequate for resistant organisms with higher MICs.
Quick Summary
| Question | Answer |
|---|---|
| Volume to infuse in? | 100 mL NS or D5W |
| Infusion duration | 30 minutes (60 min in neonates) |
| Peak concentration timing | At end of infusion (30 min mark) |
| PK type | Time-dependent (T > MIC) |
| Half-life | 6-9 hours |
| Dosing frequency | Every 12 hours (MDR/CSE) or once daily (standard) |
| Avoid mixing with | Calcium-containing fluids |
IMG_3344.jpg
IMG_3343.jpg
If the patient has septic arthritis history and right now has osteomyelitis in left tibia,known case of Sickle cell disease with 5month back history of crisis.what the best antibiotic for it? And further line of management,today posted for curretage.
analyse_media
analyse_media
Finding Sources
Finding Sources
Searching PubMed
osteomyelitis sickle cell disease treatment antibiotics management
Searching the Web
MDR ESBL E.coli osteomyelitis carbapenem resistant tigecycline fosfomycin treatment bone infection
Reading File
Finding Sources
Searching the Web
sickle cell disease perioperative management surgery exchange transfusion hydroxyurea crisis prevention
Reading File
Reading Web Page
https://www.mdpi.com/2076-0817/14/2/130
This is a high-stakes clinical case. Here is a full structured analysis:
Culture Report Summary - Mr. Harsh Sahu, 27M
Specimen: Pus | Date: 13-07-2026 | Consultant: Dr. Pankaj Kumar Patel (Orthopaedics)
Organism isolated: Escherichia coli (E. coli)
Complete Sensitivity Profile
| Antibiotic | Result | MIC |
|---|---|---|
| Amikacin | Resistant | >=64 |
| Amoxicillin/Clavulanic Acid | Resistant | >=32 |
| Cefepime | Resistant | >=32 |
| Cefoperazone/Sulbactam | Resistant | >=64 |
| Ceftriaxone | Resistant | >=64 |
| Ceftriaxone - Sulbactam EDTA | SUSCEPTIBLE | - |
| Cefuroxime | Resistant | >=64 |
| Ciprofloxacin | Resistant | >=4 |
| Colistin | Intermediate | <=0.5 |
| Ertapenem | Resistant | >=8 |
| Fosfomycin | SUSCEPTIBLE | <=16 |
| Gentamicin | Resistant | >=16 |
| Imipenem | Resistant | >=16 |
| Meropenem | Resistant | 8 |
| Piperacillin/Tazobactam | Resistant | >=128 |
| Tigecycline | SUSCEPTIBLE | <=0.5 |
| Trimethoprim/Sulfamethoxazole | Resistant | >=320 |
Interpretation: This is a Carbapenem-Resistant, ESBL+MBL-producing E. coli - an XDR (Extensively Drug-Resistant) pathogen. Resistant to ALL carbapenems (meropenem, imipenem, ertapenem). Only 3 agents are susceptible: CSE (Ceftriaxone-Sulbactam-EDTA), Fosfomycin, and Tigecycline. Colistin is intermediate.
1. ANTIBIOTIC CHOICE
Primary Recommendation: CSE (Ceftriaxone + Sulbactam + EDTA) + Fosfomycin combination
Why CSE is the anchor drug:
- It is the ONLY drug on the report explicitly tested as susceptible by formal C&S
- Proven activity against ESBL + MBL co-producers (EDTA chelates Zn²+ to deactivate MBLs)
- Anti-biofilm activity (critical for osteomyelitis, where biofilm on necrotic bone is a major barrier)
- The isolate is susceptible despite ceftriaxone alone being resistant - confirming MBL-mediated resistance that EDTA overcomes
Why add Fosfomycin (IV):
- Susceptible (MIC <=16)
- In experimental bone infection models, fosfomycin monotherapy outperforms tigecycline, gentamicin, and colistin against ESBL E. coli
- Synergizes with CSE against biofilm and MDR Enterobacterales
- Unique cell wall mechanism - no cross-resistance with beta-lactams
- Good bone penetration when given IV at high doses (16-24g/day)
Tigecycline - use as reserve/third agent if needed:
- Susceptible (MIC <=0.5) - excellent in vitro activity
- Poor serum/blood concentration (limits use for bacteremic episodes)
- Acceptable for soft tissue, bone, and joint infections
- Consider adding if CSE + Fosfomycin response is inadequate, or as step-down oral equivalent is unavailable
Recommended Regimen
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| CSE (Ceftriaxone 1g + Sulbactam 500mg + EDTA 37mg) | 1.5g | IV in 100ml NS over 30 min | Every 12 hours |
| Fosfomycin (IV) | 8g | IV over 60 min | Every 8 hours (24g/day) |
Duration: Minimum 6 weeks IV for osteomyelitis (standard for chronic/surgical osteomyelitis). Review at 4-6 weeks based on clinical, inflammatory markers (CRP, ESR), and imaging response.
2. SICKLE CELL DISEASE - SPECIAL CONSIDERATIONS
Pre-operative Assessment (Today - Curettage)
This patient had a vaso-occlusive crisis 5 months ago. Surgery is a known trigger for sickle cell crisis.
Hematology workup required:
- CBC with reticulocyte count - check baseline Hb
- HbS percentage (HPLC)
- Blood group and crossmatch (sickle cell patients have high alloimmunization risk)
- Renal function (fosfomycin is renally cleared - needs dose adjustment if GFR affected)
- LFT, coagulation screen
Transfusion decision before surgery:
- If Hb <8.5 g/dL: simple top-up transfusion to target Hb = 10 g/dL (do NOT exceed 11 g/dL - hyperviscosity risk)
- If severe phenotype (prior stroke, recurrent ACS, prior severe surgical complications): consider Red Cell Exchange (RCE) targeting HbS <30%
- Conservative transfusion (simple) is equally effective as aggressive exchange in preventing perioperative complications with fewer alloimmunization events (Preoperative Transfusion in SCD Study Group, multicenter RCT)
3. PERIOPERATIVE MANAGEMENT - CURETTAGE
Pre-operative
| Priority | Action |
|---|---|
| Hydration | Start IV fluids (0.9% NS or D5 0.45NS) 12 hours before surgery - prevent dehydration and stasis |
| Oxygenation | Maintain SpO2 >95% - hypoxia is a major sickling trigger |
| Temperature | Pre-warm OT - avoid hypothermia intraoperatively |
| Analgesia | Optimize pain control pre-op (opioids + NSAIDs as per baseline); SCD patients often have high opioid tolerance |
| Hematology consult | Mandatory - check if transfusion needed (as above) |
| Antibiotics | Give CSE 30-60 min before incision (first dose as surgical prophylaxis if not already on it) |
| Hydroxyurea | If on HU, do NOT stop - continue perioperatively |
Intraoperative
- Avoid: Hypoxia, acidosis, hypothermia, tourniquet use (vascular stasis), dehydration
- Anesthesia: Neuraxial (spinal/epidural) preferred over general if possible - reduces perioperative hypoxia risk
- If GA required: careful airway, maintain normothermia with warming blanket
- Maintain adequate hydration throughout
- Tourniquet is relatively contraindicated - if unavoidable, minimize time and deflate carefully
Surgical (Curettage of Left Tibia)
- Debride all necrotic/infected bone thoroughly - curettage must achieve clean margins
- Send intraoperative bone biopsy for repeat C&S (sinus tract/pus cultures are unreliable for determining which organisms are truly in bone)
- Consider antibiotic-impregnated beads (gentamicin or vancomycin beads) for local delivery - though gentamicin resistance exists systemically, local high concentrations may still contribute; alternatively use CSE/fosfomycin-impregnated cement beads if available
- Achieve wound closure or plan for VAC (vacuum-assisted closure) if contaminated wound
Post-operative
| Monitor | Target |
|---|---|
| SpO2 | >95% continuously for 24-48 hrs |
| Hydration | Maintain IV fluids until tolerating oral |
| Temperature | Normothermia - warming blanket |
| Pain | Multimodal analgesia - patient often has high baseline opioid needs |
| CBC | Check Hb, WBC post-op at 24 hrs and Day 3 |
| CRP/ESR | Baseline then weekly to track response |
| Renal function | Daily for first 3 days (fosfomycin, risk of AKI in SCD) |
Watch for SCD complications post-op:
- Acute Chest Syndrome (ACS) - new infiltrate + fever + chest pain/hypoxia - treat with exchange transfusion + bronchodilators
- Vaso-occlusive pain crisis - IV fluids, analgesia, O2
- Acute kidney injury - hold fosfomycin, adjust dose
4. ANTIBIOTIC DURATION AND FOLLOW-UP
| Phase | Action |
|---|---|
| Weeks 1-6 | IV CSE + IV Fosfomycin (full-dose combination) |
| Week 4 | Repeat CRP, ESR, imaging (MRI preferred) to assess bone response |
| Week 6 assessment | If responding, consider step-down to oral fosfomycin or tigecycline (if oral available and susceptible) |
| Total duration | 6-12 weeks depending on surgical clearance and inflammatory marker trend |
| Infectious disease consult | Strongly recommended for XDR organism management |
Summary - Antibiotic of Choice
CSE (Ceftriaxone-Sulbactam-EDTA) + IV Fosfomycin is the combination of choice guided by this culture report. This is an XDR E. coli resistant to all carbapenems - CSE overcomes MBL resistance, and fosfomycin provides synergistic bone-penetrating activity. Tigecycline can be added as a third agent if clinical response is poor. This patient also needs careful perioperative SCD management: avoid sickling triggers (hypoxia, cold, dehydration, acidosis), optimize Hb to ~10g/dL pre-op, and monitor closely post-curettage for ACS and VOC.
- Campbell's Operative Orthopaedics 15th Ed, p. 498-555 (Sickle Cell perioperative)
- Rosen's Emergency Medicine, p. 23-29 (Osteomyelitis in SCD)
- Al Farii et al., JAAOS 2020 - Osteomyelitis in SCD review
- MDR GNB Bone & Joint Infections - Pathogens 2025
This is a shared conversation. Sign in to Orris to start your own chat.